CHICAGO, May 01, 2018 -- Lumere, a leading provider of data-driven analytics, evidence and expert guidance to help health systems reduce unwarranted clinical variation, today announced plans to collaborate with the Association of Healthcare Value Analysis Professionals’ (AHVAP) Industry Business Education Collaborative agreement.
This agreement includes educational offerings highlighting best-practice strategies and tactics to help health systems and value analysis professionals consistently apply evidence to clinical decisions. “Hospitals and clinicians are strapped to find the time and the resources to collect the vast amounts of available drug and device information and also to dissect and separate unbiased sources from biased ones,” said Lumere Chief Development Officer Gina Thomas, RN, MBA. “AHVAP is the perfect collaborator because of its dedication to applying a clinical and evidence-based perspective to the clinical decision process.”
According to AHVAP President Susan Knapp, RN, MS, CVAHP, the two organizations share a vision to improve patient value by reducing unnecessary clinical variation and reducing costs. “Variation in care is a major contributor to wasteful healthcare spending,” she said. “Our members have the potential to play important roles in curtailing that waste, and solutions like Lumere’s offer important resources for them and their facilities.”
According to Knapp, redefining and repositioning the role of value analysis offers an exceptional opportunity to bring about real change.
“Historically, value analysis leaders have had to react quickly to market place pressures. While that doesn’t change, integrating a clinical and evidence-based approach metric into all decisions will help advance the value analysis practice,” Knapp said.
Thomas, agrees with that assessment. “Our educational offerings will emphasize the fact that value analysis must be embedded within an organization’s clinical care governance as a patient-centered, multidisciplinary approach,” she said.
About Lumere
Lumere is at the forefront of clinical decision making for drugs and devices, offering evidence-based solutions and services for all providers that improve care and reduce cost across the patient journey. For more information, visit lumere.com, find us on LinkedIn, follow @LumereHQ on Twitter and like us on Facebook.
About AHVAP
The Association of Healthcare Value Analysis Professionals (AHVAP) is an organization of professionals whose expertise bridges the gap between clinical and supply chain process. Through the use of evidence, clinical and financial expertise value analysis facilitators play a pivotal role to ensure effective decision-making that positively impacts clinical, operational and financial outcomes. For more information, visit AHVAP.org, find us on LinkedIn, follow @AHVAP on Twitter and like us on Facebook.
Media Contact
Pam Flores
[email protected]
(773) 218-9260


Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance
Continental AG Shares Jump After Q1 Profit Beats Expectations
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure
BHP Attracts AI-Focused Investors as Copper Demand Surges
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 



